Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

European Journal of Cancer

Volumn 51, Issue 11, 2015, Pages 1405-1414

  Brule S Y ^a   Jonker, D J ^a,c   Karapetis, C S ^b   O'Callaghan, C J ^c   Moore, M J ^d   Wong, R ^e   Tebbutt, N C ^f   Underhill, Cr ^g   Yip, D ^h   Zalcberg, J R ⁱ   Tu, D ^c   Goodwin, R A ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b FLINDERS UNIVERSITY   (Australia)

^c Clinical Trials Group   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e CANCERCARE MANITOBA   (Canada)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g Border Medical Oncology Australia   (Australia)

^h Calvary Retirement Community Canberra   (Australia)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Cetuximab; Colon cancer; Distal; EGfr inhibition; KRAS; Proximal

Indexed keywords

ALKALINE PHOSPHATASE; B RAF KINASE; CETUXIMAB; EPIREGULIN; HEMOGLOBIN; IRINOTECAN; K RAS PROTEIN; LACTATE DEHYDROGENASE; OXALIPLATIN; PROTEIN; PROTEIN PIK3CA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CECUM CANCER; COLORECTAL CANCER; DISEASE ASSOCIATION; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TRANSVERSE COLON; TREATMENT OUTCOME; WILD TYPE; ADULT; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84930804509     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.03.015     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.
2. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113(10):779-88.
3. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002;101(5):403-8.
4. Hansen IO, Jess P. Possible better long-term survival in left versus right-sided colon cancer - a systematic review. Dan Med J 2012;59(6):A4444.
5. Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? - A systematic review. Eur J Surg Oncol 2015;41(3):300-8.
6. Weiss JM, Pfau PR, O'Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results-medicare data. J Clin Oncol 2011;29(33):4401-9.
7. Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010;53(1):57-64.
8. Snaebjornsson P, Jonasson L, Jonsson T, Moller PH, Theodors A, Jonasson JG. Colon cancer in iceland-a nationwide comparative study on various pathology parameters with respect to right and left tumor location and patients age. Int J Cancer 2010;127(11):2645-53.
9. Suttie SA, Shaikh I, Mullen R, Amin AI, Daniel T, Yalamarthi S. Outcome of right- and left-sided colonic and rectal cancer following surgical resection. Colorectal Dis 2011;13(8):884-9.
10. Nawa T, Kato J, Kawamoto H, et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol 2008;23(3):418-23.
11. Powell AG, Wallace R, McKee RF, et al. The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer. Colorectal Dis 2012;14(12):1493-9.
12. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 2008;15(9):2388-94.
13. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357(20):2040-8.
14. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65.
15. Missiaglia E, Jacobs B, Di Narzo A, et al. Proximal and distal colon tumors as distinct biologic entities with different prognoses. 2013 ASCO Annual Meeting. 2013;Abstract 3526.
16. Heinemann V, Modest DP, von Weikersthal LF, et al. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. J Clin Oncol 32:5s, 2014 (suppl.; abstr 3600). 2014 ASCO Annual Meeting.
17. von Einem JC, Heinemann V, von Weikersthal L, Fischer, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J. Cancer Res. Clin. Oncol. 2014;140(9):1607-14.
18. Azzoni C, Bottarelli L, Campanini N, et al. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis 2007;22(2):115-26.
19. Glebov OK, Rodriguez LM, Nakahara K, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 2003;12(8):755-62.
20. Benedix F, Meyer F, Kube R, et al. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma. Pathol Res Pract 2012;208(10):592-7.
21. Kalady MF, Dejulius KL, Sanchez JA, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 2012;55(2):128-33.
22. Fric P, Sovova V, Sloncova E, Lojda Z, Jirasek A, Cermak J. Different expression of some molecular markers in sporadic cancer of the left and right colon. Eur J Cancer Prev 2000;9(4):265-8.
23. Elnatan J, Goh HS, Smith DR. C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 1996;32A(3):491-7.
24. Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol 2001;13(1):63-9.
25. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11(8):753-62.
26. Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol 2010;37(3):707-18.
27. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34.
28. Sood A, McClain D, Maitra R, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 2012;11(2):143-50.
29. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2012;23(6):1518-25.
30. Dienstmann R, Guinney J, Delorenzi M, et al. Colorectal cancer subtyping consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol 32:5s, 2014 (suppl; abstr 3511). 2014 ASCO Annual Meeting.
31. Missiaglia E, Jacobs B, Di Narzo A, et al. Proximal and distal colon tumors as distinct biologic entities with different prognoses. J Clin Oncol 31, 2013 (suppl; abstr 3526). (2013 ASCO Annual Meeting).